CNS Drugs

, Volume 7, Issue 3, pp 187–202 | Cite as

Obsessive-Compulsive Disorder

Treatment Options
  • Lawrence T. Park
  • James W. Jefferson
  • John H. Greist
Disease Management

Summary

Obsessions, compulsions and rituals have been recognised as abnormal cognitions and behaviours for several centuries. These symptoms and signs, which have been variously referred to in different ages and cultures, are encompassed under the present diagnosis of obsessive-compulsive disorder (OCD).

OCD has been an elusive nosological entity, resistant to treatment until the last 30 years. In 1966, two distinct treatment modalities, a potent serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SRI) and behavioural therapy, were introduced. Today, SRIs and behavioural therapy remain important interventions in modern OCD management, underscoring the fact that more effective modes of treatment have not been developed. Despite recent advances in understanding the underlying neurobiology of OCD, its treatment remains a challenge.

At present, the mainstay of treatment is a combination of pharmacotherapy and behavioural therapy. In terms of pharmacotherapy, the most effective class of medication remains the SRIs. Clomipramine and the selective SRIs fluoxetine, fluvoxamine, paroxetine and sertraline have all demonstrated efficacy and are regarded as first-line agents for monotherapy. If multiple trials of SRIs do not result in improvement, alternative monotherapy may be attempted with monoamine oxidase inhibitors, buspirone or clonazepam. If monotherapy achieves partial response, augmentation of SRIs or combinations of agents may be considered. Only haloperidol has demonstrated efficacy as an augmentation of an SRI in a controlled trial and only in patients with comorbid tic disorders. There is support from noncontrolled trials for some other augmenting agents.

Of the psychotherapeutic techniques, only behavioural therapy in the form of exposure and response prevention (ERP) has demonstrated significant effectiveness. Optimal results in the management of OCD are often realised through a combination of ERP and pharmacological therapy, although the availability of behavioural therapy is limited.

For the small proportion of patients who are severely disabled by prolonged treatment-resistant OCD, neurosurgery may be an effective treatment option.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rudin E. Ein Beitrag zur Frage der Zwangsdrankheit insbesondere ihrere hereditaren Beziehungen. Arch Psychiatr Nervenkr 1953; 191: 14–54Google Scholar
  2. 2.
    Jenike MA. Obsessive-compulsive and related disorders: a hidden epidemic. N Engl J Med 1989; 321: 539–41PubMedGoogle Scholar
  3. 3.
    Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094–9PubMedGoogle Scholar
  4. 4.
    Robins LN, Helzeer JI, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949–58PubMedGoogle Scholar
  5. 5.
    Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry 1994; 55(3 Suppl.): 5–10PubMedGoogle Scholar
  6. 6.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  7. 7.
    Rasmussen SA, Eisen JL. Clinical and epidemiologic findings of significance to neuropharmacologic trials in obsessive-compulsive disorder. Psychopharmacol Bull 1988; 24: 466–70PubMedGoogle Scholar
  8. 8.
    Rasmussen SA, Tsuang MT. Clinical characteristics and family history of DSM-III obsessive-compulsive disorder. Am J Psychiatry 1986; 143: 317–22PubMedGoogle Scholar
  9. 9.
    Greist JH. Treatment of obsessive-compulsive disorder: psychotherapies, drugs, and other somatic treatment. J Clin Psychiatry 1990; 51(8 Suppl.): 44–50PubMedGoogle Scholar
  10. 10.
    Yaryura-Tobias JA, Bebirian RJ, Neziroglu FA, et al. Obsessive-compulsive disorder as a serotonergic defect. Res Commun Psychol, Psychiatry Behav 1977; 2(5,6): 279–86Google Scholar
  11. 11.
    Murphy DL, Zohar J, Benkelfat C, et al. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiatry 1989; (8 Suppl.): 15-24Google Scholar
  12. 12.
    Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47(6): 577–85PubMedGoogle Scholar
  13. 13.
    Price LH. Pharmacological strategies in refractory depression. In: Tasman A, Goldfinger SM, Kaufmann CA, editors. American psychiatric press review of psychiatry, vol. 9. Washington, DC: American Psychiatric Press, 1990: 116–31Google Scholar
  14. 14.
    Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145(12): 1521–5PubMedGoogle Scholar
  15. 15.
    Pato MT, Murphy DL, De Vane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991; 11(3): 224–5PubMedGoogle Scholar
  16. 16.
    Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): long term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996; 32(1): 167–73PubMedGoogle Scholar
  17. 17.
    Fernandez CE, Lopez-Ibor JJ. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies [in Spanish; English abstract]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1967; 26: 119–47Google Scholar
  18. 18.
    van Renynghe de Voxvrie G. Use of anafranil on obsessive neuroses [in French]. Acta Neurol Belg 1968; 68(10): 787–92Google Scholar
  19. 19.
    Ananth J, Solyom L, Bryntwick S, et al. Clomipramine therapy for obsessive-compulsive neurosis. Am J Psychiatry 1979; 136: 700–20PubMedGoogle Scholar
  20. 20.
    Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281–5PubMedGoogle Scholar
  21. 21.
    Jenike MA, Baer L, Summergrad P, et al. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry 1989; 146: 1328–30PubMedGoogle Scholar
  22. 22.
    Greist JH, Jefferson JW, Rosenfeld R, et al. Clomipramine and obsessive-compulsive disorder: a placebo-controlled double-blind study in 32 patients. J Clin Psychiatry 1990; 51: 292–7PubMedGoogle Scholar
  23. 23.
    Devaugh-Geiss J, Katz R, Landau P, et al. Clomipramine in the treatment of patients with obsessive-compulsive disorder: the clomipramine collaborative study group. Arch Gen Psychiatry 1991; 48: 730–8Google Scholar
  24. 24.
    Prasad A. A double blind study of imipramine versus zimelidine in the treatment of obsessive compulsive neurosis. Pharmacopsychiatry 1984; 1(2): 61–2Google Scholar
  25. 25.
    Rasmussen SA, Goodman WK, Greist JH, et al. Fluvoxamine in the treatment of obsessive-compulsive disorder: a multi-center double-blind placebo-controlled study in outpatients. Am J Psychiatry. In pressGoogle Scholar
  26. 26.
    Tollefson GD, Rampey Jr AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51(7): 559–67PubMedGoogle Scholar
  27. 27.
    Greist JH, Chouinard G, Duboff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52(4): 289–95PubMedGoogle Scholar
  28. 28.
    Wheadon DE, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder [abstract]. Annual Meeting of the American College of Neuropsychopharmacology: 1993 Dec 13–17; Vanderbilt University: Nashville (TN)Google Scholar
  29. 29.
    Koponen H, Lepola H, Leinonen E. Citalopram in the treatment of obsessive-compulsive disorder: a report of two cases. Eur Psychiatry 1995; 10(4): 209–10PubMedGoogle Scholar
  30. 30.
    Bejerot S, Humble M. Citalopram treatment of obsessive-compulsive disorder: a pilot study of antiobsessive efficacy [abstract]. Biol Psychiatry 1991; 29: 443SGoogle Scholar
  31. 31.
    Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 53–60PubMedGoogle Scholar
  32. 32.
    Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch Gen Psychiatry 1990; 47(10): 926–32PubMedGoogle Scholar
  33. 33.
    Lopez-Ibor Jr JJ, Saiz J, Cottreaux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Eur Neuropsychopharmacol 1996; 6(2): 111–8PubMedGoogle Scholar
  34. 34.
    Freeman CPL, Trimble MR, Deakin JFW, et al. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized double-blind, parallel group comparison. J Clin Psychiatry 1994; 55(7): 301–5PubMedGoogle Scholar
  35. 35.
    Koran LM, McElroy SL, Davidson JRT, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996; 16(2): 121–9PubMedGoogle Scholar
  36. 36.
    Bisserbe JC, Wiseman RL, Goldberg MS, et al. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder (NR439) [abstract]. APA Annual Meeting: 1995 May 20-25; Miami (FL). New Research Abstracts, 1995: 173Google Scholar
  37. 37.
    Janicak PG, Davis JM, Preskorn SH, et al. Assessment and treatment of other disorders. In: Janicak PG, Davis JM, Preskorn SH, et al., editors. Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins, 1993: 449–80Google Scholar
  38. 38.
    Van Balkom AJ, Van Oppen P, Vermeulen AWA, et al. A meta-analysis on the treatment of obsessive-compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy. Clin Psychology Rev 1994; 14(5): 359–81Google Scholar
  39. 39.
    Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995; 166: 424–43PubMedGoogle Scholar
  40. 40.
    Stein DJ, Spadiccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10: 11–8PubMedGoogle Scholar
  41. 41.
    Kobak K. Behavioral versus pharmacological treatment of obsessive-compulsive disorder: a meta-analysis [dissertation]. Madison (WI): 1995, 1-143Google Scholar
  42. 42.
    Browne M, Horn E, Jones TT. The benefits of clomipramine-fluoxetine combination in obsessive-compulsive disorder. Can J Psychiatry 1993; 38(4): 242–3PubMedGoogle Scholar
  43. 43.
    Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990; 26(3): 285–90PubMedGoogle Scholar
  44. 44.
    Palova E. Combination of two SSRI’s in long-term treatment of patients with OCD — four case reports [abstract P.5.026]. 9th Congress of the European College of Neuropsychopharmacology: 1996 Sep 21–25; Amsterdam. Eur Neuropsychopharmacol 1996; 6 Suppl. 4: 148Google Scholar
  45. 45.
    Szegedi A, Wetzel H, Leal M, et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. J Clin Psychiatry 1996; 57(6): 257–64PubMedGoogle Scholar
  46. 46.
    Joel SW. Twenty month study of iproniazid therapy. Dis Nerv Syst 1959; 20: 11–4Google Scholar
  47. 47.
    Jenike MA. MAO inhibitors for obsessive-compulsive disorder [letter]. Br J Psychiatry 1982; 140: 549PubMedGoogle Scholar
  48. 48.
    Joffe RT, Swinson RP. Tranylcypromine in primary obsessive-compulsive disorder. J Anxiety Disord 1990; 4: 365–7Google Scholar
  49. 49.
    Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992; 161: 665–70PubMedGoogle Scholar
  50. 50.
    Jain VK, Swinson RP, Thomas JE. Phenelzine in obsessional neurosis. Br J Psychiatry 1970; 117: 237–8PubMedGoogle Scholar
  51. 51.
    Rihmer Z, Szantok K, Arato M, et al. Response of phobic disorders with obsessive symptoms to MAO inhibitors. Am J Psychiatry 1982; 139: 1345–6Google Scholar
  52. 52.
    Farid BT, Bulto M. Buspirone in obsessive-compulsive disorder: a prospective case study. Pharmacopsychiatry 1994: 2(5): 207–9Google Scholar
  53. 53.
    Pato MT, Pigott TA, Hill JL, et al. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 127–9PubMedGoogle Scholar
  54. 54.
    Jenike MA, Baer L. Buspirone in obsessive-compulsive disorder: an open trial. Am J Psychiatry 1988; 145: 1285–6PubMedGoogle Scholar
  55. 55.
    Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990; 147(6): 798–800PubMedGoogle Scholar
  56. 56.
    Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 1991; 1: 13–4Google Scholar
  57. 57.
    Pigott TA, L’Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12(1): 11–8PubMedGoogle Scholar
  58. 58.
    Grady TA, Pigott TA, L’Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150(5): 819–21PubMedGoogle Scholar
  59. 59.
    McDougle DJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150(4): 647–9PubMedGoogle Scholar
  60. 60.
    Hewlett WA. The use of benzodiazepines in obsessive compulsive disorder and Tourette’s syndrome. Psychiatr Ann 1993: 23: 309–16Google Scholar
  61. 61.
    Hwang EC, Van Woert MH. Antimyoclonic action of clonazepam: the role of serotonin. Eur J Pharmacol 1979; 60: 31–40Google Scholar
  62. 62.
    Wagner HR, Reches A, Yablonskaya E, et al. Clonazepam-induced up-regulation of serotonin 1 and serotonin2 binding sites in rat frontal cortex. Adv Neurol 1986; 43: 645–51PubMedGoogle Scholar
  63. 63.
    Pratt J, Jenner P, Reynolds EH, et al. Clonazepam induces decreased serotoninergic activity in the mouse brain. Neuro-pharmacology 1979; 18: 791–9Google Scholar
  64. 64.
    Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12(6): 420–30PubMedGoogle Scholar
  65. 65.
    Pigott TA, L’Heureux F, Rubenstein CS, et al. A controlled trial of clonazepam augmentation in obsessive-compulsive disorder patients treated with clomipramine or fluoxetine [abstract]. APA Annual Meeting: 1992 May 2–7; Washington, DC. New Research Abstracts 1992: 82Google Scholar
  66. 66.
    Altschuler M. Massive doses of trifluoperazine in the treatment of compulsive rituals. Am J Psychiatry 1962; 119: 367–8PubMedGoogle Scholar
  67. 67.
    Hussain MZ, Ahad A. Treatment of obsessive compulsive neurosis. Can Med Assoc J 1970; 103: 648–50PubMedGoogle Scholar
  68. 68.
    Rivers-Buckley N, Hollender MH. Successful treatment of obsessive-compulsive disorder with loxapine. Am J Psychiatry 1982; 139: 1345–6Google Scholar
  69. 69.
    Young CR, Bostic JQ, McDonald CL. Clozapine and refractory obsessive-compulsive disorder: a case report. J Clin Psychopharmacol 1994; 14(3): 209–11PubMedGoogle Scholar
  70. 70.
    McDougle CJ, Goodman WK, Aronson SC, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995; 152(12): 1812–4PubMedGoogle Scholar
  71. 71.
    Baker RW, Chengappa KNR, Baird JW, et al. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992; 53(12): 439–41PubMedGoogle Scholar
  72. 72.
    Allen L, Tejera C. Treatment of clozapine-induced obsessive compulsive symptoms with sertraline. Am J Psychiatry 1994; 151(7): 1096–7PubMedGoogle Scholar
  73. 73.
    Remington G, Adams M. Risperidone and obsessive compulsive symptoms. J Clin Psychopharmacol 1994; 14(5): 358–9PubMedGoogle Scholar
  74. 74.
    Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive compulsive symptoms in schizophrenia. Am J Psychiatry 1994; 151(11): 1714–5PubMedGoogle Scholar
  75. 75.
    Ghaemi SN, Zarate CA, Popli AP, et al. Is there a relationship between clozapine and obsessive-compulsive disorder? A retrospective chart review. Compr Psychiatry 1995; 36(4): 267–70PubMedGoogle Scholar
  76. 76.
    McDougle CJ, Leckman JF, Heninger GR. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51(4): 302–8PubMedGoogle Scholar
  77. 77.
    McDougle CJ, Goodman WK, Price LJ, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147(5): 652–4PubMedGoogle Scholar
  78. 78.
    McDougle CJ, Epperson CN, Leckman JF, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: 3 cases. J Clin Psychiatry 1995; 56(11): 526–8PubMedGoogle Scholar
  79. 79.
    Jacobsen FM. Risperidone in the treatment of severe affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56(9): 423–9PubMedGoogle Scholar
  80. 80.
    Dexfenfluramine. Lancet 1991; 337: 1315–6Google Scholar
  81. 81.
    Hollander E, DeCaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990; 51: 119–23PubMedGoogle Scholar
  82. 82.
    Judd FK, Chua P, Lynch C, et al. Fenfluramine augmentation of clomipramine treatment of obsessive compulsive disorder. Aust N Z J Psychiatry 1991; 25: 412–4PubMedGoogle Scholar
  83. 83.
    Golden RN, Morris JE, Sack DA. Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biol Psychiatry 1988; 23: 181–5PubMedGoogle Scholar
  84. 84.
    Eisenberg J, Asnis G. Lithium as an adjunct treatment in obsessive-compulsive disorder [letter]. Am J Psychiatry 1985; 142: 663PubMedGoogle Scholar
  85. 85.
    Feder R. Lithium augmentation of clomipramine [letter]. J Clin Psychiatry 1988; 49: 458PubMedGoogle Scholar
  86. 86.
    McDougle DJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11(3): 175–84PubMedGoogle Scholar
  87. 87.
    Pigott TA, Pato MT, L’Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11(4): 242–8PubMedGoogle Scholar
  88. 88.
    Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry 1992; 53(4 Suppl.): 29–37PubMedGoogle Scholar
  89. 89.
    Hussain MZ, Ahad A. Treatment of obsessive-compulsive neurosis. Can Med Assoc J 1970; 103: 648–50PubMedGoogle Scholar
  90. 90.
    Turner SM, Hersen M, Bellack AS, et al. Behavioral and pharmacological treatment of obsessive-compulsive disorders. J Nerv Ment Dis 1980; 168: 651–7PubMedGoogle Scholar
  91. 91.
    Snyder S. Amitriptyline therapy of obsessive-compulsive neurosis. J Clin Psychiatry 1980; 41: 286–9PubMedGoogle Scholar
  92. 92.
    Anath J, Solyom L, Solyom C, et al. Doxepin in the treatment of obsessive-compulsive neurosis. Psychosomatics 1975; 16: 185–7Google Scholar
  93. 93.
    Foa EF, Steketee G, Kozak MJ, et al. Imipramine and placebo in the treatment of obsessive-compulsives: their effect on depression and on obsessional symptoms. Psychopharmacol Bull 1987; 23: 8–11PubMedGoogle Scholar
  94. 94.
    Hollander E, Mullen L, De Caria CM, et al. Obsessive compulsive disorder, depression and fluoxetine. J Clin Psychiatry 1991; 52: 418–22PubMedGoogle Scholar
  95. 95.
    Hermesh H, Aizenberg D, Munitz H. Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol 1992; 13(4): 322–8Google Scholar
  96. 96.
    Pigott TA, L’Heureux F, Rubenstein CS, et al. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12(3): 156–62PubMedGoogle Scholar
  97. 97.
    Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine [letter]. J Clin Psychopharmacol 1990; 10: 152–3PubMedGoogle Scholar
  98. 98.
    Rauch SL, O’Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases [letter]. J Clin Psychopharmacol 1996; 16(1): 81–4PubMedGoogle Scholar
  99. 99.
    Yaryura-Tobias JA, Neziroglu FA, McKay DR. The action of venlafaxine on obsessive-compulsive disorder [abstract]. Biol Psychiatry 1994; 35: 737Google Scholar
  100. 100.
    Montgomery SA, Fineberg N, Montgomery D, et al. L-tryptophan in obsessive-compulsive disorder — a placebo controlled study [abstract]. Vth Congress of the European College of Neuropsychopharmacology; 1992 Oct 18–21; Marbella, Spain, 127. Eur Neuropsychopharmacol 1992; 2 (3): 384-5Google Scholar
  101. 101.
    Cohen DJ, Detlor J, Young JG, et al. Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980; 37: 1350–7PubMedGoogle Scholar
  102. 102.
    Knesevich JW. Successful treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1982; 7: 278–9Google Scholar
  103. 103.
    Lipsedge MS, Prothero W. Clonidine and clomipramine in obsessive-compulsive disorder [letter]. Am J Psychiatry 1987; 144: 965–6PubMedGoogle Scholar
  104. 104.
    Insel TR, Hamilton J, Guttmacher L, et al. d-Amphetamine in obsessive-compulsive disorder. Psychopharmacology 1983; 80: 231–5PubMedGoogle Scholar
  105. 105.
    Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 1983; 140: 1219–20PubMedGoogle Scholar
  106. 106.
    Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette’s syndrome. Int J Neurosci 1987; 35: 93–4PubMedGoogle Scholar
  107. 107.
    Casas M, Alvarez E, Curo P, et al. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986; 73(2): 221–2PubMedGoogle Scholar
  108. 108.
    Chouinard G, Belanger MC, Sultan S, et al. Potentiation of fluoxetine by aminoglutethimide steroid suppression in obsessive-compulsive disorder: a case report [abstract]. APA Annual Meeting: 1995 May 20-2; Miami (FL). New Research Abstracts, 1995: 162Google Scholar
  109. 109.
    Ceccherini-Nelli A, Guazzelli M. Treatment of refractory obsessive-compulsive disorder with the dopamine agonist bromocriptine. J Clin Psychiatry 1994; 55(9): 415–6PubMedGoogle Scholar
  110. 110.
    Deltito JA. Valproate pretreatment for the difficult-to-treat patient with obsessive-compulsive disorder [letter]. J Clin Psychiatry 1994; 55(11): 500PubMedGoogle Scholar
  111. 111.
    Den Boer JA, Westenberg HG. Oxytocin in obsessive-compulsive disorder. Peptides 1992; 13(6): 1083–5Google Scholar
  112. 112.
    Salzberg AD, Swedo SE. Oxytocin and vasopressin in obsessive-compulsive disorder. Am J Psychiatry 1992; 149(5): 713–4PubMedGoogle Scholar
  113. 113.
    Smeraldi E, Mundo E, Erzegovesi S. 5HT-3 receptor and anti-obsessional effect. Human Psychopharmacol 1992; 7(4): 291–2Google Scholar
  114. 114.
    Erzegovesi S, Ronchi P, Smeraldi E. 5HT-2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Human Psychopharmacol 1992; 7(4): 287–9Google Scholar
  115. 115.
    Lopez-Ibor JJ. Intravenous infusions of monochlorimipramine. Technique and results. Sixth International Congress of the CINP; 1968 Apr; Taragona. Excerpta Medica Foundation Int Congress Series No. 180. Amsterdam, 1969: 519–21Google Scholar
  116. 116.
    Warneke L. Intravenous chlorimipramine therapy in obsessive- compulsive disorder. Can J Psychiatry 1989; 34(9): 853–9PubMedGoogle Scholar
  117. 117.
    Fallon BA, Campeas R, Schneier FR, et al. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 70–5PubMedGoogle Scholar
  118. 118.
    Greist JH. Behavior therapy for obsessive-compulsive disorder. J Clin Psychiatry 1994; 55(10 Suppl.): 60–8PubMedGoogle Scholar
  119. 119.
    Marks IM. Fears, phobias and rituals. New York: Oxford University Press, 1987Google Scholar
  120. 120.
    Baer L, Minichiello WE. Behavior therapy of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, editors. Obsessive-compulsive disorders: theory and management, 2nd ed. Chicago: Year Book Medical Publishers, Inc., 1990: 203–32Google Scholar
  121. 121.
    Marks IM. Living with fear. New York (NY): McGraw-Hill, 1978Google Scholar
  122. 122.
    Baer L. Getting control. Boston: Little, Brown, 1991Google Scholar
  123. 123.
    Foa EB, Wilson R. Stop obsessing! New York (NY): Bantam, 1991Google Scholar
  124. 124.
    Neziroglu F, Yaryura-Tobias JA. Over and over again: understanding obsessive-compulsive disorder. Lexington (MA): Lexington Books, 1991Google Scholar
  125. 125.
    Steketee GS, White K. When once is not enough. Oakland (CA): New Harbinger Press, 1990Google Scholar
  126. 126.
    Greist JH. Obsessive-compulsive disorder: a guide. Obsessive Compulsive Information Center, Dean Foundation for Health, Research and Education: Madison, 1995Google Scholar
  127. 127.
    Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980; 136: 1–25PubMedGoogle Scholar
  128. 128.
    Marks IM, Lelliot P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988; 152: 522–34PubMedGoogle Scholar
  129. 129.
    Cottraux J, Mollard E, Bouvard M, et al. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res 1993; 49(1): 63–75PubMedGoogle Scholar
  130. 130.
    March J. Treatment of childhood obsessive compulsive disorder anxiety disorders [abstract]. 2nd Australian Conference on Obsessive-Compulsive Disorder: 1994 May 13–14. Obsessive-Compulsive Disorder Support Groups-NSW Association for Mental Health, Gadesville, Australia, 1994: 9Google Scholar
  131. 131.
    Orloff LM, Battle MA, Baer L, et al. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 1994; 151(3): 441–2PubMedGoogle Scholar
  132. 132.
    Wever CL. Multi-modal treatment of childhood obsessive-compulsive disorder [abstract]. 2nd Australian Conference on Obsessive-Compulsive Disorder: 1994 May 14–15. Obsessive-Compulsive Disorder Support Groups-NSW Association for Mental Health, Gadesville, Australia, 1994: 10Google Scholar
  133. 133.
    Lucey JV, Butcher G, Clare AW, et al. The clinical characteristics of patients with obsessive-compulsive disorder: a descriptive study of an Irish sample. Ir J Psychological Med 1994; 11(1): 11–4Google Scholar
  134. 134.
    Pato MT. When to discontinue pharmacologic treatment. In: Jenike MA, Baer L, Minichiello WE, editors. Obsessive-compulsive disorders: theory and management, 2nd ed. Chicago: Year Book Medical Publishers, Inc., 1990: 312–22Google Scholar
  135. 135.
    Foa EB, Steketee GS, Ozarow BJ. Behavior therapy with obsessive-compulsive disorder: from theory to treatment. In: Mavissakalian M, Turner SM, Michelson L, editors. Obsessive-compulsive disorder: psychological and pharmacological treatment. New York: Plenum Press, 1985: 49–129Google Scholar
  136. 136.
    Baxter Jr LR, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 681–9PubMedGoogle Scholar
  137. 137.
    Schwartz JM, Stoessel PW, Baxter LR, et al. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53: 109–13PubMedGoogle Scholar
  138. 138.
    Turner SM, Beidel DC, Spaulding SA, et al. The practice of behavior therapy: a national survey of cost and methods. Behav Therapist 1995; 18(1): 1–4Google Scholar
  139. 139.
    Greist JH. Computer-administered behavior therapists. Int Rev Psychiatry 1989; 1: 267–74Google Scholar
  140. 140.
    Greist JH. Behavioral therapy — reviewing techniques and new technologies in obsessive-compulsive disorder [abstract]. OCD ’95 — 1st International Congress on Education and Progress in OCD; 1995 Jun 23; Barcelona, SpainGoogle Scholar
  141. 141.
    Jenike MA, Rauch SL. ECT for OCD [letter]. J Clin Psychiatry 1995; 56(2): 81–2Google Scholar
  142. 142.
    Maletzky B, McFarland B, Burt A. Refractory OCD and ECT. Convuls Ther 1994; 10(1): 34–42Google Scholar
  143. 143.
    Hay, Sachdev P, Cumming S, et al. Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand 1993; 87(3): 197–207PubMedGoogle Scholar
  144. 144.
    Mindus P, Jenike MA. Neurosurgical treatment of malignant obsessive-compulsive disorder. Psychiatr Clin North Am 1992; 15(4): 921–38PubMedGoogle Scholar
  145. 145.
    Baer L, Rauch SL, Ballantine Jr HT, et al. Cingulotomy for intractable obsessive-compulsive disorder: prospective long-term follow-up of 18 patients. Arch Gen Psychiatry 1995; 52(5): 384–92PubMedGoogle Scholar
  146. 146.
    Bean WB. Osler: aphorisms. New York (NY): Henry Shuman, Inc., 1950; No. 211: 101Google Scholar
  147. 147.
    Jefferson JW, Altemus M, Greist JH, et al. International psycho-pharmacology algorithm project report: E. Algorithm for the pharmacologic treatment of obsessive-compulsive disorder (OCD). Reported at the NCDEU meeting; 1995 May–Jun; Orlando (FL). Psychopharmacol Bull 1995; 31(3): 487–500, 505-7PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Lawrence T. Park
    • 1
  • James W. Jefferson
    • 1
  • John H. Greist
    • 1
  1. 1.Research and EducationMadisonUSA

Personalised recommendations